Matthew Weston
Stock Analyst at UBS
(2.49)
# 2,421
Out of 5,058 analysts
5
Total ratings
100%
Success rate
10.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DBX Dropbox | Assumes: Sell | $29 → $27 | $29.19 | -7.50% | 1 | Sep 18, 2025 | |
| NVO Novo Nordisk | Downgrades: Neutral | n/a | $49.00 | - | 1 | Aug 5, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | n/a | $127.31 | - | 1 | Feb 13, 2025 | |
| AZN AstraZeneca | Upgrades: Buy | n/a | $88.99 | - | 2 | Feb 13, 2025 |
Dropbox
Sep 18, 2025
Assumes: Sell
Price Target: $29 → $27
Current: $29.19
Upside: -7.50%
Novo Nordisk
Aug 5, 2025
Downgrades: Neutral
Price Target: n/a
Current: $49.00
Upside: -
Novartis AG
Feb 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $127.31
Upside: -
AstraZeneca
Feb 13, 2025
Upgrades: Buy
Price Target: n/a
Current: $88.99
Upside: -